Baidu
map

AACE 2016:糖尿病患者长途旅行时,怎么办?

2016-05-30 QQduhq 译 MedSci原创

一项新的研究指出,跨越多个时区的航空旅行可能需要糖尿病患者重新调整糖尿病药物的使用。5月27日美国临床内分泌学协会2016年会上,Rahul Suresh博士通过对13篇文章进行综合分析评估提出这项结论。Suresh提出,糖尿病患者旅行时会面临很多风险,尤其是跨多个时区更是如此。他们必须提前做好准备,需要调整胰岛素剂量或口服糖尿病药物。通过适当的调整,可降低他们出现低血糖等并发症的风险并保证旅途安

一项新的研究指出,跨越多个时区的航空旅行可能需要糖尿病患者重新调整糖尿病药物的使用。5月27日美国临床内分泌学协会2016年会上,Rahul Suresh博士通过对13篇文章进行综合分析评估提出这项结论。


Suresh提出,糖尿病患者旅行时会面临很多风险,尤其是跨多个时区更是如此。他们必须提前做好准备,需要调整胰岛素剂量或口服糖尿病药物。通过适当的调整,可降低他们出现低血糖等并发症的风险并保证旅途安全。

数据显示,高达10%的糖尿病患者在旅行期间会遇到许多并发症,最常见的是低血糖。因此需要动用紧急医疗设施进行抢救,甚至需要飞机迫降或转运。若糖尿病患者向西旅行,他们易出现高血糖,若糖尿病患者向东旅行,则易出现低血糖,这些主要是由于时差因素。此外,在飞机上注射胰岛素也会出现剂量的准确性问题。如果飞机在上升过程中有可能导致注射剂量过大,如果飞机在下降过程中则会导致胰岛素泵出障碍,这主要是由于环境压力因素。Ratner博士指出,尽管没有糖尿病患者自诉飞机上出现胰岛素使用障碍报告,但是这有可能是个问题。他曾经遇到患者自诉胰岛素笔出现气泡的事例。

Suresh博士和同事对13篇有关高空旅行与胰岛素分泌关系的文章进行了分析。其中11篇为专家观点,其余两篇分别为前瞻性队列研究和横断面调查。

基于这些信息,他们提出了针对糖尿病患者长途旅行的建议:
患者餐前速效或短效胰岛素及胰岛素增敏剂不需调整剂量,然而,患者向东旅行时应携带促分泌素(磺脲类和格列奈类),在旅行期间都应携带SGLT2抑制剂,因为患者有可能会出现脱水风险。中长效胰岛素剂量的调整因人而异,这取决于患者平时的注射剂量。

若乘客自西向东旅行,则由于会出现低血糖风险,应减少基础胰岛素剂量,减少剂量为:正常剂量x时区交叉的数量/基础胰岛素注射时间间隔小时数。在出发地点注射剂量为调整后的胰岛素剂量,到达目的地后的注射剂量为正常注射剂量。 

若患者自东向西旅行,则会出现高血糖风险,则可适当增加胰岛素注射剂量。对于注射胰岛素1次的糖尿病患者而言,则应在出发地快速注射一半的胰岛素剂量,到达目的地后再注射原剂量的一半。对于安装了胰岛素泵的患者而言,研究人员指出,患者不需每日调整剂量,泵入机体胰岛素的时间应设置为到达目的地的时间。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1655744, encodeId=7b2d1655e4450, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Feb 21 23:58:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699192, encodeId=7fb116991923a, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Thu Jul 28 07:58:00 CST 2016, time=2016-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127547, encodeId=efd212e547c8, content=感谢分享,指导很仔细, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160907/IMG57D00CF1965701770.jpg, createdBy=565c1948251, createdName=舒心和人, createdTime=Thu Sep 15 14:31:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88130, encodeId=8a0f8813057, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:37:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473983, encodeId=3ba014e3983c6, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jun 01 00:58:00 CST 2016, time=2016-06-01, status=1, ipAttribution=)]
    2017-02-21 shanyongle
  2. [GetPortalCommentsPageByObjectIdResponse(id=1655744, encodeId=7b2d1655e4450, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Feb 21 23:58:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699192, encodeId=7fb116991923a, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Thu Jul 28 07:58:00 CST 2016, time=2016-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127547, encodeId=efd212e547c8, content=感谢分享,指导很仔细, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160907/IMG57D00CF1965701770.jpg, createdBy=565c1948251, createdName=舒心和人, createdTime=Thu Sep 15 14:31:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88130, encodeId=8a0f8813057, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:37:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473983, encodeId=3ba014e3983c6, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jun 01 00:58:00 CST 2016, time=2016-06-01, status=1, ipAttribution=)]
    2016-07-28 zgwhgch
  3. [GetPortalCommentsPageByObjectIdResponse(id=1655744, encodeId=7b2d1655e4450, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Feb 21 23:58:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699192, encodeId=7fb116991923a, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Thu Jul 28 07:58:00 CST 2016, time=2016-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127547, encodeId=efd212e547c8, content=感谢分享,指导很仔细, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160907/IMG57D00CF1965701770.jpg, createdBy=565c1948251, createdName=舒心和人, createdTime=Thu Sep 15 14:31:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88130, encodeId=8a0f8813057, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:37:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473983, encodeId=3ba014e3983c6, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jun 01 00:58:00 CST 2016, time=2016-06-01, status=1, ipAttribution=)]
    2016-09-15 舒心和人

    感谢分享,指导很仔细

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1655744, encodeId=7b2d1655e4450, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Feb 21 23:58:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699192, encodeId=7fb116991923a, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Thu Jul 28 07:58:00 CST 2016, time=2016-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127547, encodeId=efd212e547c8, content=感谢分享,指导很仔细, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160907/IMG57D00CF1965701770.jpg, createdBy=565c1948251, createdName=舒心和人, createdTime=Thu Sep 15 14:31:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88130, encodeId=8a0f8813057, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:37:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473983, encodeId=3ba014e3983c6, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jun 01 00:58:00 CST 2016, time=2016-06-01, status=1, ipAttribution=)]
    2016-06-02 沉心多思

    好文章,得多学习了!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1655744, encodeId=7b2d1655e4450, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Feb 21 23:58:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699192, encodeId=7fb116991923a, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Thu Jul 28 07:58:00 CST 2016, time=2016-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127547, encodeId=efd212e547c8, content=感谢分享,指导很仔细, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160907/IMG57D00CF1965701770.jpg, createdBy=565c1948251, createdName=舒心和人, createdTime=Thu Sep 15 14:31:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88130, encodeId=8a0f8813057, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=189, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:37:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473983, encodeId=3ba014e3983c6, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jun 01 00:58:00 CST 2016, time=2016-06-01, status=1, ipAttribution=)]

相关资讯

AACE 2016:肥胖的2型糖尿病患者,其炎症标志物显著增加

研究结果显示,在2型糖尿病的肥胖患者中,超敏C反应蛋白水平和白细胞计数均增加。肥胖和糖化血红蛋白水平之间未发现相关性。来自沃洛沃大学的David Soyoye博士和同事对155名2型糖尿病患者(平均年龄56.5岁,有66名男性)进行了交叉型研究,评估肥胖、糖化血红蛋白水平和炎症标记物之间的关系。数据显示,男性和女性的平均BMI分别为25.8 kg/m2和29.2 kg/m2;其中BMI>30 kg

什么是代谢手术?

在20世纪后半叶,研究人员想通过外科手术(如肠旁路术)来治疗高脂血症和高胆固醇等一系列代谢性疾病。1995年,Walter博士和他的研究小组发表了一篇名为“谁能想到?手术竟是治疗成人起病的糖尿病最有效的手段”。自从那一篇具有里程碑意义的论文发表后,逐渐出现很多证据表明,手术可以治愈/改善一些代谢性疾病,特别是成人起病的糖尿病或2型糖尿病。2009年,美国减肥手术协会(ASB)更名为美国代谢和减肥手

糖尿病手术疗法进临床指南

本周美国糖尿病学会期刊《Diabetes Care》上,发表了信的2型糖尿病治疗临床指南,这次公布的指南近100年来最大的一次修改。国际上45个专业学会共同支持该指南的修改。指南建议胃转流等手术是适当糖尿病患者的标准治疗方法。这次修改是依据多个临床试验证明这种手术可比任何生活方式和药物干预更有效地改善血糖水平,并可以带来长期病情缓解。历经全球糖尿病医学领域20多年的潜心研究和临床实践,胃转流手术已

Nature Medicine:一次治疗有望持久缓解糖尿病

根据5月23日《自然—医学》在线发表的一篇论文,给小鼠和大鼠注射一次针对大脑调节血糖回路的激素,可以长久缓解糖尿病。

全球首部2型糖尿病代谢手术治疗联合指南出台

2016年5月24日,全球首部由多个国际上糖尿病组织参与制定的关于代谢手术治疗2型糖尿病的指南:“代谢手术作为2型糖尿病治疗方案:国际糖尿病组织联合声明”在线发表于美国糖尿病协会(ADA)官方杂志Diabetes Care。

AACE 2016:补充维生素D有望缓解糖尿病视网膜病变

研究者称,糖尿病视网膜病变患者与健康对照组相比,更有可能出现较低的25羟维生素D水平。纽约巴塞特医学中心医学系的Anawin Sanguankeo博士在AACE科学和临床会议上说:“维生素D可能在糖尿病视网膜病变的病理生理中起着一定的作用。在未来应该对维生素D能否预防糖尿病性视网膜病变或进展进行更多的研究。”他说,现在已知维生素D缺乏与一些心血管并发症有关,包括胰岛素分泌、代谢综合征和全身性糖尿病

Baidu
map
Baidu
map
Baidu
map